Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Found 205 studies with search of: | "Alemtuzumab" |
Rank | Status | Study | ||||
---|---|---|---|---|---|---|
1 | Recruiting |
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
|
||||
2 | Recruiting |
Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia
|
||||
3 | Active, not recruiting |
Fludara Plus Alemtuzumab (Campath, MabCampath) vs Fludara Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients
|
||||
4 | Active, not recruiting |
Safety and Efficacy of Campath in Nonmyeloablative Transplantation
|
||||
5 | Recruiting |
Alemtuzumab and Pentostatin In T-Cell Neoplasms
|
||||
6 | Recruiting |
Alemtuzumab + Rituximab Consolidation in CLL
|
||||
7 | Recruiting |
A Phase I Study of Alemtuzumab Delivered Intraperitoneally in Patients With Relapsed Ovarian Cancer
|
||||
8 | Recruiting |
Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias
|
||||
9 | Completed |
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
|
||||
10 | Recruiting |
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
|
||||
11 | Active, not recruiting |
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response
|
||||
12 | Active, not recruiting |
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy
|
||||
13 | Recruiting |
Alemtuzumab to Treat Severe Aplastic Anemia
|
||||
14 | Recruiting |
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
|
||||
15 | Completed |
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
|
||||
16 | Recruiting |
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
|
||||
17 | Recruiting |
Alemtuzumab (Campath® (Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia
|
||||
18 | Completed |
Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia or T-Lymphoblastic Lymphoma With MabCampath
|
||||
19 | Active, not recruiting |
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
|
||||
20 | Recruiting |
Alemtuzumab and CHOP in T-Cell Lymphoma
|
Previous Page | Studies Shown (1-20) | Next Page (21-40) |